Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is for men with recurrent metastatic, castration-resistant prostate cancer. 
    

Key Inclusion / Exclusion Criteria:

   • Men age 18 and older 
   • Diagnosis of histological, pathological,and/or cytological confirmation of prostate cancer 
   • Detailed eligibility reviewed when you contact the study team. 

Combining radiotherapy and immunotherapy is promising and has advantages. Since radiation therapy is given to particular area in your body is does not have many side effects that are commonly seen in patients receiving chemotherapy.

Key Inclusion / Exclusion Criteria:
  1. Open to Men and women, ages > 18 years of age. 
  2. Patients must demonstrate the ability to understand and the willingness to sign a written informed consent document. 
  3. Any prior therapy is permitted except prior therapy with PD1/PDL1 inhibitor. 
  4. Patients must have documented evidence of histologic diagnosis of metastatic renal cell carcinoma or urothelial cancer; 
  5. Patients must have at least 2 distinct measurable metastatic sites at least 1 cm or larger in their largest diameter per RECIST 1.1. 
  6. Performance status ECOG 0-1 
  7. Life expectancy > 3 months 
  8. Stable brain metastases for at least 4 weeks and not steroid dependent 

The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of your muscle invasive bladder cancer. MK-3475 is a drug that uses a person’s own immune system to treat cancer.

Key Inclusion / Exclusion Criteria:

- Muscle-invasive urothelial carcinoma of the bladder or upper tract 
- Radical surgical resection of the bladder cancer has taken place greater than or equal to 4 weeks but less than or equal to 16 weeks prior to pre-registration. 
- No evidence of residual cancer or metastasis after surgery 
- No active autoimmune disease or one that might recur 
- No current pneumonitis or prior history of non-infection pneumonitis that required steroids in the past 5 years 
- No known active Hepatitis B or Hepatitis C 
- No postoperative/adjuvant systemic therapy 
- Not pregnant and not nursing 
- Less than or equal to 4 weeks before pre-registration 
- No treatment with any other type of investigational agent 
- No major surgery 
- No radiation therapy 
- No neoadjuvant chemotherapy 
- Detailed eligibility reviewed when you contact the study team

The purpose of this research study is to collect long term safety information on HUMIRA® (adalimumab), a monoclonal antibody approved for the treatment of moderate to severely active ulcerative colitis (UC).

Key Inclusion / Exclusion Criteria:

A patient will be eligible for participation in this registry if he/she meets inclusion criteria 1 and 3 or 2 and 3: 
    
   1. An adult patient (18 years of age or older) with moderately to severely active Ulcerative Colitis (UC) as per the physician's assessment who has been prescribed HUMIRA®, without or in combination with an immunomodulator (IMM) (6-MP (6-Mercaptopurine) or AZA (Azathioprine)), according to the local product labeling and meets one of the following criteria: 
    
   ● Is currently taking HUMIRA® therapy, and has received at least 8 weeks of HUMIRA® therapy prior to registry entry and the physician can provide source documentation (if available and/or applicable) of Serious Adverse Events (SAEs), Adverse Events of Interests (AEIs), and dosing information since initiation of therapy; 
    
   OR 
    
   ● Is entering after participation in an Abbott or AbbVie sponsored UC study and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy since initiation of therapy. 
    
   2. An adult patient (18 years of age or older) with moderately to severely active UC as per the physician's assessment who has been prescribed IMM (6-MP or AZA) therapy, is currently taking IMM (6-MP or AZA) therapy without a concurrent biologic, has received at least 12 consecutive weeks of IMM therapy prior to registry entry and the physician can provide source documentation (if available and/or applicable) of SAEs, AEIs, and dosing information since initiation of therapy. 
    
   3. Patient is capable of and willing to grant authorization for use/disclosure of data being collected and provided to AbbVie and to comply with the requirements of the Registry protocol.

Exclusion Criteria 

   ● On HUMIRA® therapy if they cannot be treated with HUMIRA® in accordance with the local product label or 
   ● On IMM (6-MP or AZA) therapy without a concurrent biologic if they cannot continue to be treated with IMM therapy. 

Patients should not be enrolled into the registry if they are being treated with any investigational agents and/or approved biologics other than HUMIRA®.

The purpose of this study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help control MDS. The safety of each study drug given on these schedules will also be studied. This is an investigational study.

Key Inclusion / Exclusion Criteria:

   - Subjects age 18 years or older. 
   - Low- or intermediate-risk myelodysplastic syndrome. 
   - Adequate performance status. 
   - Adequate organ function. 
   *Detailed eligibility criteria will be reviewed when you contact the study team. 

This is a multi-center phase II study evaluating the efficacy of ruxolitinib in PTCL. Patients with rel/ref PTCL following at least 1 systemic therapy will enroll onto one of three of the following cohorts: 
    

Key Inclusion / Exclusion Criteria:

• Pathologically confirmed T or NK cell lymphoma at the enrolling institution. For CTCL, patients with stage IB disease or greater are eligible. 
• Relapse or refractory disease after at least 1 systemic therapy 
• Age ≥ 18 
Detailed eligibility reviewed when you contact the study team.

This clinical trial is for men and women ages 18 and older with follicular lymphoma with detectable BCL2-t or mantle cell lymphoma with presence of cyclin D1 overexpression (can be newly diagnosed or relapsed).

Key Inclusion / Exclusion Criteria:

   - Men and women age 18 and older 
   - Follicular lymphoma or Mantle cell lymphoma 
   - Detailed eligibility reviewed when you contact the study team

This clinical trial is for men and women, 18 years of age and older, who either have advanced solid tumors that have progressed with standard treatment, do not have standard therapy for their cancer, or for patients who seek therapy that will convey clinical benefit but are not available, and a m

Key Inclusion / Exclusion Criteria:

- Open to men and women age 18 or older 

- Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies) 

- Detailed eligibility reviewed when you contact the study team 

  • This study is for men and women with relapsed or refractory multiple myeloma, who have had at least two prior anti-myeloma regimens. 
  • This study is being done to test if SGN-CD352A is safe to give to patients with myeloma, and will test what the best dose of SGN-CD352A is for myeloma
Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • A confirmed diagnosis of symptomatic multiple myeloma and measureable secretory disease 
  • ECOG performance score of 0 or 1 
  • At least 2 prior anti-myeloma regimens that you responded to, with a regimen that included a proteasome inhibitor and immunomodulatory agent (IMiD) 
  •  Detailed eligibility reviewed when you contact the study team 

This clinical trial is for men and women with superficial bladder cancer that has not invaded into the bladder muscle wall and that did not respond to Bacillus Calmette‐Guerin (BCG).

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • Patients must have non‐muscle invasive urothelial cancer of the bladder that is either Stage T1 High‐Grade, Stage CIS, or Stage Ta High‐Grade.     
  • Patients must have all visible tumor resected completely within 60 days prior to starting the study. 
  • Patients must have been treated with BCG, and was unresponsive to treatment.
  • Detailed eligibility reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.